Advanced search
Publication Cover
Cancer Management and Research Volume 16, 2024 - Issue
Submit an article Journal homepage
103
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Crossing the River by Feeling the Stones: Experiences with PD-1 Inhibitors in Geriatric Oncology People, a Case Report and Literature Review

Hang Yin1 Oncology Department, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, People’s Republic of ChinaORCID Iconhttps://orcid.org/0009-0006-0870-9040
ORCID Icon,
Xia Zhang2 Oncology Department, Dalian Fifth People’s Hospital, Dalian, 116000, People’s Republic of China
,
Manjie Zhang1 Oncology Department, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, People’s Republic of ChinaORCID Iconhttps://orcid.org/0009-0000-8963-1252
ORCID Icon,
Hong Tang1 Oncology Department, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, People’s Republic of China
,
Chunxia Zhang1 Oncology Department, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, People’s Republic of China
&
Jia Li1 Oncology Department, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, People’s Republic of ChinaCorrespondence[email protected] [email protected]
Pages 87-93 | Received 29 Nov 2023, Accepted 25 Jan 2024, Published online: 05 Feb 2024

References

  • Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. PMID: 26808342. doi:10.3322/caac.21338
  • Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer. 1997;33(14):2313–2314. PMID: 9616273. doi:10.1016/s0959-8049(97)10050-8
  • Presley C, Lilenbaum R. The treatment of advanced lung cancer in the elderly: the role of a comprehensive geriatric assessment and doublet chemotherapy. Cancer J. 2015;21(5):392–397. PMID: 26389764. doi:10.1097/PPO.0000000000000145
  • Nadpara PA, Madhavan SS, Tworek C, Sambamoorthi U, Hendryx M, Almubarak M. Guideline-concordant lung cancer care and associated health outcomes among elderly patients in the United States. J Geriatr Oncol. 2015;6(2):101–110. PMID: 25604094; PMCID: PMC4450093. doi:10.1016/j.jgo.2015.01.001
  • Nasser NJ, Gorenberg M, Agbarya A. First line immunotherapy for non-small cell lung cancer. Pharmaceuticals. 2020;13(11):373. PMID: 33171686; PMCID: PMC7695295. doi:10.3390/ph13110373
  • Wu YL, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: checkMate 078 randomized Phase III clinical trial. J Thorac Oncol. 2019;14(5):867–875. PMID: 30659987. doi:10.1016/j.jtho.2019.01.006
  • Blasi M, Kuon J, Shah R, et al. Pembrolizumab alone or with chemotherapy for 70+ year-old lung cancer patients: a retrospective study. Clin Lung Cancer. 2023;24(7):e282–e290. PMID: 37391339. doi:10.1016/j.cllc.2023.06.010
  • Paz-Ares L, Luft A, Vicente D, et al.; KEYNOTE-407 Investigators. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040–2051. PMID: 30280635. doi:10.1056/NEJMoa1810865
  • Zhou N, Jiang M, Li T, et al. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: an open-label, dose escalation and expansion study. Lung Cancer. 2021;160:111–117. PMID: 34482102. doi:10.1016/j.lungcan.2021.08.006
  • Middleton G, Brock K, Savage J, et al. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med. 2020;8(9):895–904. PMID: 32199466. doi:10.1016/S2213-2600(20)30033-3
  • Lee SM, Schulz C, Prabhash K, et al. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. Lancet. 2023. 402(10400):451–463. Erratum in: Lancet. 2023;402(10400):450. PMID: 37423228. doi:10.1016/S0140-6736(23)00774-2
  • Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021:39(36):4073–4126. doi:10.1200/JCO.21.01440
  • Daniello L, Elshiaty M, Bozorgmehr F, et al. Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer. Front Oncol. 2021;11:703893. PMID: 34268127; PMCID: PMC8277237. doi:10.3389/fonc.2021.703893

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.